Friday, 21 October 2011

MS breakthrough


www.medpagetoday.com
AMSTERDAM -- Efficacy and safety data from a phase III trial of dimethyl fumarate (BG12) in relapsing-remitting multiple sclerosis were impressive enough to elicit a wow when they were shared with n

No comments:

Post a Comment